We are live on ! Find out more
CMND icon

Clearmind Medicine
CMND

1 hedge funds and large institutions have $260K invested in Clearmind Medicine in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

90% more capital invested

Capital invested by funds: $137K → $260K (+$123K)

31.77% less ownership

Funds ownership: 34.7% → 2.92% (-32%)

80% less funds holding

Funds holding: 5 → 1 (-4)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 4

Holders
1
Holders Change
-4
Holders Change %
-80%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AI
AdvisorShares Investments
Maryland
+$352K

Top Sellers

Rank Fund Capital Flow
1
Walleye Capital
Walleye Capital
New York
-$61.7K
2
WAM
Warberg Asset Management
Illinois
-$35.2K
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$10.2K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$7.96K
5
Citadel Advisors
Citadel Advisors
Florida
-$2.35K

CMND Hedge Fund Activity: Q4 2023 in Review

1 of the 6,872 institutional investors tracked by Wall St. Rank reported a position in Clearmind Medicine (CMND) for Q4 2023, worth a combined $260K — up 90% from $137K a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of CMND and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was AdvisorShares Investments, adding an estimated $352K. The largest seller was Walleye Capital, exiting entirely with an estimated $61.7K sold.

  • 1 institutional investor held Clearmind Medicine (CMND) as of Q4 2023, down from 5 in Q3 2023.
  • Funds reported $260K of Clearmind Medicine stock for Q4 2023, up 90% quarter-over-quarter.
  • 0 funds opened new Clearmind Medicine positions in Q4 2023 and 4 closed out, a net change of -4 holders.
  • The largest Clearmind Medicine buyer in Q4 2023 was AdvisorShares Investments, an estimated $352K added.
  • The largest Clearmind Medicine seller in Q4 2023 was Walleye Capital, an estimated $61.7K sold.

Based on aggregated 13F filings for Q4 2023.